Evidence map›Paper›PMID 27221700›Full record

ArticleHepatology international2016

End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients.

Joseph Ahn, Taft Bhuket, Sasan Mosadeghi, Catherine Frenette, Benny Liu, Robert J Wong

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph AhnSchool of Medicine, University of California, San Francisco, CA, USA.
Taft BhuketEndoscopy Unit, Division of Gastroenterology and Hepatology, Alameda Health System-Highland Hospital, 1411 East 31st Street, Highland Hospital-Highland Care Pavilion 5th Floor, Oakland, CA, 94602, USA.
Sasan MosadeghiEndoscopy Unit, Division of Gastroenterology and Hepatology, Alameda Health System-Highland Hospital, 1411 East 31st Street, Highland Hospital-Highland Care Pavilion 5th Floor, Oakland, CA, 94602, USA.
Catherine FrenetteDepartment of Organ Transplantation, Scripps Green Hospital, San Diego, CA, USA.
Benny LiuEndoscopy Unit, Division of Gastroenterology and Hepatology, Alameda Health System-Highland Hospital, 1411 East 31st Street, Highland Hospital-Highland Care Pavilion 5th Floor, Oakland, CA, 94602, USA.
Robert J WongEndoscopy Unit, Division of Gastroenterology and Hepatology, Alameda Health System-Highland Hospital, 1411 East 31st Street, Highland Hospital-Highland Care Pavilion 5th Floor, Oakland, CA, 94602, USA. Rowong@alamedahealthsystem.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsStatus 1A patients are prioritized over end-stage liver disease (ESLD) for liver transplantation (LT). ESLD patients with high MELD may have higher waitlist mortality than Status 1A patients, and may require LT more urgently.

methodsUsing United Network for Organ Sharing registry data, we retrospectively evaluated LT waitlist mortality and probability of LT between adults in the United States with Status 1A or ESLD with MELD >30 listed for LT from 2003-2013. Overall waitlist mortality and probability of LT were evaluated with Kaplan-Meier and multivariate logistic regression models.

resultsFrom 2003-2013, 15,049 ESLD patients with MELD >30 and 3049 Status 1A patients were listed for LT. While overall 14-day waitlist survival decreased with increasing MELD score among ESLD patients (54.0 % for MELD 31-35; 37.1 % for MELD 36-40; 27.5 % for MELD >40), overall survival at 14 days was significantly lower among Status 1A (14.4 %). Compared to Status 1A, ESLD patients with MELD >40 had significantly higher 14-day waitlist mortality (OR 1.92; 95 % CI 1.56-2.36; p < 0.001), whereas ESLD patients with MELD 36-40 had a non-significant trend towards higher waitlist mortality (OR 1.16; 95 % CI 0.93-1.45; p = 0.181). No difference in probability of LT within 14 days was observed between ESLD with MELD >40 and Status 1A (p = 0.89). ESLD patients with MELD >40 had higher post-LT survival compared to Status 1A on multivariate regression modeling (HR 0.80; 95 % CI 0.66-0.96; p < 0.02).

conclusionAmong adults in the United States awaiting LT, ESLD patients with MELD >40 have significantly higher waitlist mortality, but similar probability of receiving LT compared to Status 1A patients.

Indexed as

AdultAgedEnd Stage Liver DiseaseFemaleHumansLiver TransplantationMaleMiddle AgedOrgan Dysfunction ScoresRegistriesRetrospective StudiesUnited StatesWaiting ListsLiver failureLiver transplantationStatus 1AUNOS/OPTNWaitlist survival

Identifiers

PMID27221700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.